Polymer-lipid hybrid nanovesicle-enabled combination of immunogenic chemotherapy and RNAi-mediated PD-L1 knockdown elicits antitumor immunity against melanoma

NIR-Triggered Phototherapy and Immunotherapy via an Antigen-Capturing Nanoplatform for Metastatic Cancer Treatment

(2019) Meng Wang et al.   Advanced Science

Cancer nanomedicine for combination cancer immunotherapy

(2019) Jutaek Nam et al.   Nature Reviews Materials

Nanoenabled Reversal of IDO1-Mediated Immunosuppression Synergizes with Immunogenic Chemotherapy for Improved Cancer Therapy

(2019) Hua Huang et al.   NANO LETTERS

Covalent Organic Framework‐Supported Molecularly Dispersed Near‐Infrared Dyes Boost Immunogenic Phototherapy against Tumors

(2019) Shaoju Gan et al.   ADVANCED FUNCTIONAL MATERIALS

Multiplexed activation of endogenous genes by CRISPRa elicits potent antitumor immunity

(2019) Guangchuan Wang et al.   NATURE IMMUNOLOGY

Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups

(2019) Lawrence P. Andrews et al.   NATURE IMMUNOLOGY

Co-localized delivery of nanomedicine and nanovaccine augments the postoperative cancer immunotherapy by amplifying T-cell responses

(2019) Xiang Liu et al.   BIOMATERIALS

Nanoparticle-mediated Immunogenic Cell Death Enables and Potentiates Cancer Immunotherapy

(2018) Xiaopin Duan et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

The study of relationships between pKa value and siRNA delivery efficiency based on tri-block copolymers

(2018) Lili Du et al.   BIOMATERIALS

Engineering Dendritic-Cell-Based Vaccines and PD-1 Blockade in Self-Assembled Peptide Nanofibrous Hydrogel to Amplify Antitumor T-Cell Immunity

(2018) Pengxiang Yang et al.   NANO LETTERS

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

(2018) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immune-Related Adverse Events Associated with Immune Checkpoint Blockade

(2018) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Personalized vaccines for cancer immunotherapy

(2018) Ugur Sahin et al.   SCIENCE

Cancer immunotherapy using checkpoint blockade

(2018) Antoni Ribas et al.   SCIENCE

Chemo-photothermal therapy combination elicits anti-tumor immunity against advanced metastatic cancer

(2018) Jutaek Nam et al.   Nature Communications

Analysis of PARP inhibitor toxicity by multidimensional fluorescence microscopy reveals mechanisms of sensitivity and resistance

(2018) Jone Michelena et al.   Nature Communications

Dendritic cell-mediated delivery of doxorubicin-polyglycerol-nanodiamond composites elicits enhanced anti-cancer immune response in glioblastoma

(2018) Tong-Fei Li et al.   BIOMATERIALS

Breast Cancer Chemo-immunotherapy through Liposomal Delivery of an Immunogenic Cell Death Stimulus Plus Interference in the IDO-1 Pathway

(2018) Jianqin Lu et al.   ACS Nano

Nano-, micro-, and macroscale drug delivery systems for cancer immunotherapy

(2018) Pingsheng Huang et al.   Acta Biomaterialia

Biopolymers codelivering engineered T cells and STING agonists can eliminate heterogeneous tumors

(2017) Tyrel T. Smith et al.   JOURNAL OF CLINICAL INVESTIGATION

Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer

(2017) Ugur Sahin et al.   NATURE

An immunogenic personal neoantigen vaccine for patients with melanoma

(2017) Patrick A. Ott et al.   NATURE

Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma

(2016) Avery D. Posey et al.   IMMUNITY

Neoantigen landscape dynamics during human melanoma–T cell interactions

(2016) Els M. E. Verdegaal et al.   NATURE

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

(2016) Weiping Zou et al.   Science Translational Medicine

The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma

(2015) Kathleen M. Mahoney et al.   CLINICAL THERAPEUTICS

Therapeutic cancer vaccines

(2015) Cornelis J.M. Melief et al.   JOURNAL OF CLINICAL INVESTIGATION

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma

(2015) M. Callea et al.   Cancer Immunology Research

In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas

(2014) K. A. Schalper et al.   CLINICAL CANCER RESEARCH

Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia

(2014) M. L. Davila et al.   Science Translational Medicine

PD-L1 Expression in Triple-Negative Breast Cancer

(2014) E. A. Mittendorf et al.   Cancer Immunology Research

The effect of autophagy inhibitors on drug delivery using biodegradable polymer nanoparticles in cancer treatment

(2013) Xudong Zhang et al.   BIOMATERIALS

Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments

(2013) H Inoue et al.   CELL DEATH AND DIFFERENTIATION

Oncology Meets Immunology: The Cancer-Immunity Cycle

(2013) Daniel S. Chen et al.   IMMUNITY

Tumour heterogeneity and cancer cell plasticity

(2013) Corbin E. Meacham et al.   NATURE

Nivolumab plus Ipilimumab in Advanced Melanoma

(2013) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Severe Cutaneous and Neurologic Toxicity in Melanoma Patients during Vemurafenib Administration Following Anti-PD-1 Therapy

(2013) D. B. Johnson et al.   Cancer Immunology Research

Immunogenic Cell Death in Cancer Therapy

(2012) Guido Kroemer et al.   Annual Review of Immunology